Literature DB >> 24329023

Determining the utility of intraoperative magnetic resonance imaging for transsphenoidal surgery: a retrospective study.

Jan Coburger1, Ralph König, Klaus Seitz, Ute Bäzner, Christian Rainer Wirtz, Michal Hlavac.   

Abstract

OBJECT: Intraoperative MRI (iMRI) provides updated information for neuronavigational purposes and assessments on the status of resection during transsphenoidal surgery (TSS). The high-field technique additionally provides information about vascular structures at risk and precise information about extrasellar residual tumor, making it readily available during the procedure. The imaging, however, extends the duration of surgery. To evaluate the benefit of this technique, the authors conducted a retrospective study to compare postoperative outcome and residual tumor in patients who underwent conventional microsurgical TSS with and without iMRI.
METHODS: A total of 143 patients were assessed. A cohort of 67 patients who had undergone surgery before introduction of iMRI was compared with 76 patients who had undergone surgery since iMRI became routine in TSS at the authors' institution. Residual tumor, complications, hormone dependency, biochemical remission rates, and improvement of vision were assessed at 6-month follow-up. A volumetric evaluation of residual tumor was performed in cases of parasellar tumor extension.
RESULTS: The majority of patients in both groups suffered from nonfunctioning pituitary adenomas. At the 6-month follow-up assessment, vision improved in 31% of patients who underwent iMRI-assisted surgery versus 23% in the conventional group. One instance of postoperative intrasellar bleeding was found in the conventional group. No major complications were found in the iMRI group. Minor complications were seen in 9% of patients in the iMRI group and in 5% of those in the conventional group. No differences between groups were found for hormone dependency and biochemical remission rates. Time of surgery was significantly lower in the conventional treatment group. Overall a residual tumor was found after surgery in 35% of the iMRI group, and 41% of the conventional surgery group harbored a residual tumor. Total resection was achieved as intended significantly more often in the iMRI group (91%) than in the conventional group (73%) (p < 0.034). Patients with a planned subtotal resection showed higher mean volumes of residual tumor in the conventional group. There was a significantly lower incidence of intrasellar tumor remnants in the iMRI group than in the conventional group. Progression-free survival after 30 months was higher according to Kaplan-Meier analysis with the use of iMRI, but a statistically significant difference could not be shown.
CONCLUSIONS: The use of high-field iMRI leads to a significantly higher rate of complete resection. In parasellar tumors a lower residual volume and a significantly lower rate of intrasellar tumor remnants were shown with the technique. So far, long-term follow-up is limited for iMRI. However, after 2 years Kaplan-Meier analyses show a distinctly higher progression-free survival in the iMRI group. No significant benefit of iMRI was found for biochemical remission rates and improvement of vision. Even though the surgical time was longer with the adjunct use of iMRI, it did not increase the complication rate significantly. The authors therefore recommend routine use of high-field iMRI for pituitary surgery, if this technique is available at the particular center.

Entities:  

Mesh:

Year:  2013        PMID: 24329023     DOI: 10.3171/2013.9.JNS122207

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  Intraoperative magnetic resonance imaging assessment of non-functioning pituitary adenomas during transsphenoidal surgery.

Authors:  Kunal S Patel; Yong Yao; Renzhi Wang; Bob S Carter; Clark C Chen
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

Review 2.  Intraoperative MR Imaging in Neurosurgery.

Authors:  S Bisdas; C Roder; U Ernemann; M S Tatagiba
Journal:  Clin Neuroradiol       Date:  2015-08-11       Impact factor: 3.649

Review 3.  The experience with transsphenoidal surgery and its importance to outcomes.

Authors:  Jürgen Honegger; Florian Grimm
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 4.  Intraoperative magnetic resonance imaging.

Authors:  M Hlavac; C R Wirtz; M-E Halatsch
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

Review 5.  iMRI During Transsphenoidal Surgery.

Authors:  Prashant Chittiboina
Journal:  Neurosurg Clin N Am       Date:  2017-08-18       Impact factor: 2.509

6.  Identification of tumor residuals in pituitary adenoma surgery with intraoperative MRI: do we need gadolinium?

Authors:  Georg Gohla; Benjamin Bender; Marcos Tatagiba; Jürgen Honegger; Ulrike Ernemann; Constantin Roder
Journal:  Neurosurg Rev       Date:  2019-11-14       Impact factor: 3.042

Review 7.  Intraoperative MRI for Brain Tumors.

Authors:  Cara Marie Rogers; Pamela S Jones; Jeffrey S Weinberg
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

8.  Combined high-field intraoperative magnetic resonance imaging and endoscopy increase extent of resection and progression-free survival for pituitary adenomas.

Authors:  Peter T Sylvester; John A Evans; Gregory J Zipfel; Richard A Chole; Ravindra Uppaluri; Bruce H Haughey; Anne E Getz; Julie Silverstein; Keith M Rich; Albert H Kim; Ralph G Dacey; Michael R Chicoine
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

9.  Intraoperative ultrasound in pediatric brain tumors: does the surgeon get it right?

Authors:  Ash Singhal; A Ross Hengel; Paul Steinbok; D Doug Cochrane
Journal:  Childs Nerv Syst       Date:  2015-08-05       Impact factor: 1.475

10.  Investigating the application of diving endoscopic technique in determining the extent of pituitary adenoma resection via the trans-nasal-sphenoidal approach.

Authors:  Hai-Bin Gao; Li-Qing Wang; Jian-Yun Zhou; Wei Sun
Journal:  Exp Ther Med       Date:  2018-03-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.